{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T17:48:20Z","timestamp":1777312100926,"version":"3.51.4"},"reference-count":36,"publisher":"Hamad bin Khalifa University Press (HBKU Press)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Obesity and type 2 diabetes mellitus (T2DM) are modern-day pandemics that have a significant impact on global healthcare. The glucagon-like peptide-1 receptor agonist (GLP1-RA) semaglutide is a novel treatment for both T2DM and obesity, but can be associated with an increased risk of venous thromboembolism.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Case presentation:<\/jats:bold>\n                    This case report describes a 59-year-old woman with T2DM who received semaglutide to manage glycemic levels, and also experienced the additional benefit of weight reduction. Within six months of initiating GLP1-RA, the patient experienced low back pain associated with nausea and poor oral intake. She had no known risk factors for venous thromboembolism or thrombophilia and had no history of significant illness in her family. Her physical examination revealed no significant findings. Only mild leukocytosis and neutrophilia were noted. She underwent an abdominal computed tomography scan, which revealed intrahepatic portal vein thrombosis without evidence of liver cirrhosis or abdominal malignancy. Her symptoms improved with oral anticoagulation (rivaroxaban). The result of thrombophilia examination was negative for inherited or acquired thrombophilia, except for a Janus kinase 2 mutation, which may increase the risk of thrombosis.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    The use of GLP1-RA is increasing due to the growing desire for weight loss medications. Therefore, it is important that physicians better understand the possible risks of thrombosis before initiating GLP1-RA treatment.\n                  <\/jats:p>","DOI":"10.5339\/qmj.2024.75","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T03:50:43Z","timestamp":1736394643000},"source":"Crossref","is-referenced-by-count":4,"title":["Portal vein thrombosis in a patient on semaglutide"],"prefix":"10.5339","volume":"2024","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6238-7907","authenticated-orcid":true,"given":"Mohammed F.","family":"Farooqi","sequence":"first","affiliation":[{"name":"Internal Medicine, Tawam Hospital, Al Ain, UAE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0334-076X","authenticated-orcid":true,"given":"Maria","family":"Khan","sequence":"additional","affiliation":[{"name":"Internal Medicine, Tawam Hospital, Al Ain, UAE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arshad M.","family":"Muhammad","sequence":"additional","affiliation":[{"name":"Internal Medicine, Tawam Hospital, Al Ain, UAE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2704-8931","authenticated-orcid":true,"given":"Adnan","family":"Agha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3277","reference":[{"key":"CIT0001","series-title":"StatPearls Publishing","article-title":"BMI classification percentile and cut off points. In: StatPearls. Treasure Island (FL):","author":"Weir\n \nCB\n,","year":"2023"},{"issue":"(9403):","key":"CIT0002","series-title":"Lancet","first-page":"157\u2013163","article-title":"Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies","volume":"363","year":"2004"},{"issue":"(4):","key":"CIT0003","series-title":"Cell Metab","first-page":"740\u2013756","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker\n \nDJ","year":"2018"},{"issue":"10:","key":"CIT0004","series-title":"Front Endocrinol (Lausanne)","first-page":"155. doir","article-title":"The discovery and development of liraglutide and semaglutide","author":"Knudsen\n \nLB\n,","year":"2019"},{"issue":"(10278):","key":"CIT0005","series-title":"Lancet","first-page":"971\u2013984","article-title":"Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomized, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies\n \nM\n,","year":"2021"},{"issue":"(3):","key":"CIT0006","series-title":"J Clin Exp Hepatol","first-page":"965\u2013979","article-title":"Portal vein thrombosis in cirrhosis","volume":"12","author":"Shukla\n \nA\n,","year":"2022"},{"issue":"(Suppl. S3):","key":"CIT0007","series-title":"J Gastroenterol Hepatol","first-page":"S224\u2013S227","article-title":"Spectrum of portal vein thrombosis in the West","volume":"17","author":"Valla\n \nD-C.","year":"2002"},{"issue":"(5):","key":"CIT0008","series-title":"J Hepatol","first-page":"736\u2013741","article-title":"Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis","volume":"40","author":"Amitrano\n \nL\n,","year":"2004"},{"issue":"(6):","key":"CIT0009","series-title":"Gastroenterology","first-page":"1582\u20131599.e1","article-title":"Diagnosis, development, and treatment of portal vein thrombosis in patients with and without cirrhosis","volume":"156","author":"Intagliata\n \nNM\n,","year":"2019"},{"issue":"(1):","key":"CIT0010","series-title":"Hepatology","first-page":"210\u2013218","article-title":"Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study","volume":"51","author":"Plessier\n \nA\n,","year":"2010"},{"issue":"(4):","key":"CIT0011","series-title":"Gastroenterology","first-page":"1063\u20131069","article-title":"Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders","volume":"94","author":"Valla\n \nD\n,","year":"1988"},{"issue":"(5):","key":"CIT0012","series-title":"Ind J Gastroenterol","first-page":"629\u2013641","article-title":"Prothrombotic states in portal vein thrombosis and Budd-Chiari syndrome in India: a systematic review and meta-analysis","volume":"42","author":"Giri\n \nS\n,","year":"2023"},{"issue":"(1):","key":"CIT0013","series-title":"Haematologica","first-page":"70\u201381","article-title":"Vascular endothelial cell expression of JAK2(V617F) is sufficient to promote a pro-thrombotic state due to increased P-selectin expression","volume":"104","author":"Guy\n \nA\n,","year":"2019"},{"issue":"(4):","key":"CIT0014","series-title":"Ind J Hematol Blood Transfus","first-page":"700\u2013704","article-title":"JAK2V617F Mutation in Patient with Splanchnic Vein Thrombosis","volume":"36","author":"Kumar\n \nN\n,","year":"2020"},{"issue":"(3):","key":"CIT0015","series-title":"J Thromb Thrombolysis","first-page":"388\u2013396","article-title":"The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis","volume":"34","author":"Yonal\n \nI\n,","year":"2012"},{"issue":"(4):","key":"CIT0016","series-title":"Open J Prev Med","first-page":"449\u2013509","article-title":"The effects of obesity on venous thromboembolism: A review","volume":"2","author":"Yang\n \nG\n,","year":"2012"},{"issue":"(6):","key":"CIT0017","series-title":"Endocr J","first-page":"739\u2013742","article-title":"Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials","volume":"68","author":"Yin\n \nDG\n,","year":"2021"},{"issue":"(12):","key":"CIT0018","series-title":"Cureus","first-page":"e50051","article-title":"An atypical presentation of dulaglutide-induced pancreatitis complicated by superior mesenteric vein thrombosis","volume":"15","author":"Manuel\n \nSL\n,","year":"2023"},{"key":"CIT0001","series-title":"StatPearls Publishing","article-title":"BMI classification percentile and cut off points. In: StatPearls. Treasure Island (FL):","author":"Weir\n \nCB\n,","year":"2023"},{"issue":"(9403):","key":"CIT0002","series-title":"Lancet","first-page":"157\u2013163","article-title":"Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies","volume":"363","year":"2004"},{"issue":"(4):","key":"CIT0003","series-title":"Cell Metab","first-page":"740\u2013756","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker\n \nDJ","year":"2018"},{"issue":"10:","key":"CIT0004","series-title":"Front Endocrinol (Lausanne)","first-page":"155. doir","article-title":"The discovery and development of liraglutide and semaglutide","author":"Knudsen\n \nLB\n,","year":"2019"},{"issue":"(10278):","key":"CIT0005","series-title":"Lancet","first-page":"971\u2013984","article-title":"Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomized, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies\n \nM\n,","year":"2021"},{"issue":"(3):","key":"CIT0006","series-title":"J Clin Exp Hepatol","first-page":"965\u2013979","article-title":"Portal vein thrombosis in cirrhosis","volume":"12","author":"Shukla\n \nA\n,","year":"2022"},{"issue":"(Suppl. S3):","key":"CIT0007","series-title":"J Gastroenterol Hepatol","first-page":"S224\u2013S227","article-title":"Spectrum of portal vein thrombosis in the West","volume":"17","author":"Valla\n \nD-C.","year":"2002"},{"issue":"(5):","key":"CIT0008","series-title":"J Hepatol","first-page":"736\u2013741","article-title":"Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis","volume":"40","author":"Amitrano\n \nL\n,","year":"2004"},{"issue":"(6):","key":"CIT0009","series-title":"Gastroenterology","first-page":"1582\u20131599.e1","article-title":"Diagnosis, development, and treatment of portal vein thrombosis in patients with and without cirrhosis","volume":"156","author":"Intagliata\n \nNM\n,","year":"2019"},{"issue":"(1):","key":"CIT0010","series-title":"Hepatology","first-page":"210\u2013218","article-title":"Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study","volume":"51","author":"Plessier\n \nA\n,","year":"2010"},{"issue":"(4):","key":"CIT0011","series-title":"Gastroenterology","first-page":"1063\u20131069","article-title":"Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders","volume":"94","author":"Valla\n \nD\n,","year":"1988"},{"issue":"(5):","key":"CIT0012","series-title":"Ind J Gastroenterol","first-page":"629\u2013641","article-title":"Prothrombotic states in portal vein thrombosis and Budd-Chiari syndrome in India: a systematic review and meta-analysis","volume":"42","author":"Giri\n \nS\n,","year":"2023"},{"issue":"(1):","key":"CIT0013","series-title":"Haematologica","first-page":"70\u201381","article-title":"Vascular endothelial cell expression of JAK2(V617F) is sufficient to promote a pro-thrombotic state due to increased P-selectin expression","volume":"104","author":"Guy\n \nA\n,","year":"2019"},{"issue":"(4):","key":"CIT0014","series-title":"Ind J Hematol Blood Transfus","first-page":"700\u2013704","article-title":"JAK2V617F Mutation in Patient with Splanchnic Vein Thrombosis","volume":"36","author":"Kumar\n \nN\n,","year":"2020"},{"issue":"(3):","key":"CIT0015","series-title":"J Thromb Thrombolysis","first-page":"388\u2013396","article-title":"The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis","volume":"34","author":"Yonal\n \nI\n,","year":"2012"},{"issue":"(4):","key":"CIT0016","series-title":"Open J Prev Med","first-page":"449\u2013509","article-title":"The effects of obesity on venous thromboembolism: A review","volume":"2","author":"Yang\n \nG\n,","year":"2012"},{"issue":"(6):","key":"CIT0017","series-title":"Endocr J","first-page":"739\u2013742","article-title":"Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials","volume":"68","author":"Yin\n \nDG\n,","year":"2021"},{"issue":"(12):","key":"CIT0018","series-title":"Cureus","first-page":"e50051","article-title":"An atypical presentation of dulaglutide-induced pancreatitis complicated by superior mesenteric vein thrombosis","volume":"15","author":"Manuel\n \nSL\n,","year":"2023"}],"container-title":["Qatar Medical Journal"],"original-title":[],"link":[{"URL":"https:\/\/www.qscience.com\/view\/journals\/qmj\/2024\/4\/article-75.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.qscience.com\/downloadpdf\/journals\/qmj\/2024\/4\/article-75.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.qscience.com\/downloadpdf\/journals\/qmj\/2024\/4\/article-75.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T17:12:14Z","timestamp":1777309934000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.qscience.com\/view\/journals\/qmj\/2024\/4\/article-75.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":36,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.5339\/qmj.2024.75","relation":{},"ISSN":["2227-0426"],"issn-type":[{"value":"2227-0426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]}}}